Scarica l'app Stockscreener
49.78
0.18%
-0.09
Pre-mercato:
50.70
0.92
+1.85%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$49.87
Aprire:
$49.415
Volume 24 ore:
10.87M
Relative Volume:
0.77
Capitalizzazione di mercato:
$168.76B
Reddito:
$45.44B
Utile/perdita netta:
$16.18B
Rapporto P/E:
13.70
EPS:
3.634
Flusso di cassa netto:
$9.21B
1 W Prestazione:
+5.42%
1M Prestazione:
-27.78%
6M Prestazione:
-39.14%
1 anno Prestazione:
-61.68%
Intervallo 1D:
$49.38
$50.30
Intervallo di 1 settimana:
$45.05
$51.30
Portata 52W:
$45.05
$139.74
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NVO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
49.78 | 221.59B | 45.44B | 16.18B | 9.21B | 3.634 |
|
LLY
Lilly Eli Co
|
639.43 | 569.45B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
172.78 | 418.62B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
198.64 | 350.91B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
119.31 | 229.50B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
80.30 | 199.90B | 63.62B | 16.41B | 14.72B | 6.49 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-05 | Downgrade | UBS | Buy → Neutral |
| 2025-07-31 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-30 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Neutral |
| 2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Iniziato | Argus | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Downgrade | UBS | Neutral → Sell |
| 2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Downgrade | Liberum | Hold → Sell |
| 2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-05-11 | Downgrade | UBS | Buy → Neutral |
| 2020-05-04 | Iniziato | Cowen | Market Perform |
| 2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
| 2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
Real time scanner hits for Novo Nordisk A s (b Shares) Adrhedged explainedBuy/Sell Zone Confirmation Technical Analysis - Newser
Will a bounce in Novo Nordisk A s (b Shares) Adrhedged offer an exitNext Day Momentum Stock Forecasting Report - Newser
European ADRs Tick Up As Healthcare And Industrials Shine - Finimize
Applying sector rotation models to Novo Nordisk A s (b Shares) AdrhedgedPredictive AI Signals for Short-Term Trading - Newser
Why Novo Nordisk A s (b Shares) Adrhedged stock attracts strong analyst attentionIntraday Strategy with Real Time Monitoring - Newser
Does Novo Nordisk A s (b Shares) Adrhedged qualify in momentum factor screeningFree Market Surge Signal for Swing Traders - Newser
Published on: 2025-08-06 19:02:41 - Newser
Novo Nordisk Earnings: CVS Deal, Oral Semaglutide Support Growth Despite Compounding Uncertainty - Morningstar
Is Novo Nordisk A s (b Shares) Adrhedged trending in predictive chart modelsFree AI Screening for Swing Trade Picks - Newser
Novo Nordisk lowers 2025 sales outlook, ADR price falls 21.83%. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/SNVO - cnhinews.com
Novo Nordisk ADR earnings beat by $0.04, revenue fell short of estimates - Investing.com
Novo Nordisk A/S Announces 7% Increase in Interim Dividend for 2025, Payment Dates Set - AInvest
Novo Nordisk ADR earnings beat by $11.56, revenue topped estimates - Investing.com India
How to monitor Novo Nordisk A s (b Shares) Adrhedged with trend dashboardsFree Alpha Focused Technical Trade Signals - Newser
Chart based exit strategy for Novo Nordisk A s (b Shares) AdrhedgedVolume Confirmed Setup with Entry Confidence - Newser
Novo Nordisk A s (b Shares) Adrhedged’s volatility index tracking explainedMomentum Prediction Based on AI Backtesting - Newser
Novo faces shareholder lawsuit over guidance cut - MSN
Novo Nordisk ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
Is Novo Nordisk A s (b Shares) Adrhedged forming a bottoming baseHistorical Stock Summary and ROI Review - Newser
Will earnings trigger a reversal in Novo Nordisk A s (b Shares) AdrhedgedMarket Correction Proof Stock Screening Analysis - Newser
What makes Novo Nordisk A s (b Shares) Adrhedged stock price move sharplyOver 200% growth - Jammu Links News
How many analysts rate Novo Nordisk A s (b Shares) Adrhedged as a “Buy”Superior investment outcomes - Jammu Links News
Published on: 2025-08-03 21:00:40 - Jammu Links News
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - GlobeNewswire Inc.
How volatile is Novo Nordisk A s (b Shares) Adrhedged stock compared to the marketSkyrocketing returns - Jammu Links News
How strong is Novo Nordisk A s (b Shares) Adrhedged company’s balance sheetOutstanding trading profits - Jammu Links News
Should I hold or sell Novo Nordisk A s (b Shares) Adrhedged stock in 2025Unlock real-time trading signals for gains - Jammu Links News
Is Novo Nordisk A s (b Shares) Adrhedged a growth stock or a value stockAchieve explosive financial results today - Jammu Links News
How does Novo Nordisk A s (b Shares) Adrhedged compare to its industry peersUnlock rapid growth potential in your portfolio - Jammu Links News
Published on: 2025-08-03 07:55:16 - Jammu Links News
What institutional investors are buying Novo Nordisk A s (b Shares) Adrhedged stockTremendous financial leverage - Jammu Links News
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.04%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):